AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Captrust Financial Advisors

Captrust Financial Advisors lessened its stake in AstraZeneca PLC (NASDAQ:AZN) by 5.5% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 137,133 shares of the company’s stock after selling 8,001 shares during the quarter. Captrust Financial Advisors’ holdings in AstraZeneca were worth $10,684,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Rockefeller Capital Management L.P. lifted its position in shares of AstraZeneca by 1.7% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 160,335 shares of the company’s stock worth $12,480,000 after purchasing an additional 2,739 shares during the last quarter. Hantz Financial Services Inc. boosted its position in shares of AstraZeneca by 0.9% during the 3rd quarter. Hantz Financial Services Inc. now owns 44,514 shares of the company’s stock worth $3,468,000 after acquiring an additional 402 shares in the last quarter. PEAK6 Investments LLC increased its holdings in shares of AstraZeneca by 16.1% in the 3rd quarter. PEAK6 Investments LLC now owns 18,001 shares of the company’s stock valued at $1,402,000 after acquiring an additional 2,501 shares during the last quarter. Financial Counselors Inc. raised its position in shares of AstraZeneca by 4.4% during the 3rd quarter. Financial Counselors Inc. now owns 6,833 shares of the company’s stock worth $532,000 after acquiring an additional 287 shares in the last quarter. Finally, FORA Capital LLC purchased a new stake in AstraZeneca during the third quarter worth approximately $2,580,000. 20.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have weighed in on AZN. TD Cowen raised their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Finally, UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $89.75.

AstraZeneca Stock Performance

NASDAQ AZN opened at $67.62 on Monday. The firm has a market cap of $209.66 billion, a P/E ratio of 32.35, a P/E/G ratio of 1.24 and a beta of 0.47. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68. The business’s 50-day moving average price is $72.27 and its 200 day moving average price is $77.44. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The business had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. During the same quarter in the previous year, the company posted $0.87 earnings per share. The company’s revenue for the quarter was up 18.0% compared to the same quarter last year. On average, equities research analysts expect that AstraZeneca PLC will post 4.1 earnings per share for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.